A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe. The agent stimulates the body's immune system to recognize the agent as foreign, destroy it, and "remember" it, so that the immune system can more easily recognize and destroy any of these microorganisms that it later encounters.
Although several people think of medicines as purely synthetic compounds, nature is an important element of most of the medications humans depend on.
Exposure to SARS-CoV-2 by infection or vaccination generates immune cells that provide long-term immunity. These long-lived memory T cells play a key role in preventing severe cases of Covid-19. Researchers at the University of Zurich have now discovered how these memory T cells form.
New genomics research conducted by the University of Liverpool will aid in the development and implementation of vaccinations against Shigella.
Scientists at La Jolla Institute for Immunology (LJI) have found that four COVID-19 vaccines (Pfizer-BioNTech, Moderna, J&J/Janssen, and Novavax) prompt the body to make effective, long-lasting T cells against SARS-CoV-2.
Scripps Research scientists have found a mechanism that may be able to bypass one of the critical steps in current vaccine production.
The omicron variant can partly evade the antibody response provided by vaccination or infection with previous variants of SARS-CoV-2.
A new study has illustrated that people having higher levels of T cells from common cold coronaviruses are not likely to get infected with SARS-CoV-2.
AMSBIO has announced new additions to its portfolio of tools for COVID-19 research - two monoclonal antibodies that recognize the Spike RBD (B.1.1.529, Omicron Variant) protein and neutralizes its interaction with ACE2.
The Omicron variant was detected for the first time in South Africa in November 2021 and has since spread to many countries.
A new study by researchers from the University of Pennsylvania shows that experimental immunotherapy can temporarily reprogram the immune cells of patients.
Breakthrough infections greatly enhance immune response to variants of the virus that causes COVID-19, according to a newly published study from Oregon Health & Science University.
Professor Yuichi Oike and his group of researchers recently produced a peptide vaccine that mitigates conditions of dyslipidemia.
In this interview, we speak to researchers from the University of Toronto about their latest research that investigated the role genes play in the development of antibodies.
Driving up the immune response at the site of a cancer tumor with nanotechnology may help enhance immunotherapy treatments in advanced stages of the disease, new research in mice suggests.
As any parent knows, infants are prone to getting respiratory infections. But a new study shows that the infant immune system is stronger than most people think and beats the adult immune system at fighting off new pathogens.
Antibodies produced by the immune system against the SARS-CoV-2 spike protein help pinpoint and avoid future infections.
Endemic in Western African countries, Lassa virus is transmitted to humans through food or household items that are contaminated with the urine or faeces of Mastomys rats.
Biomedical engineers at Duke University have devised a test to quickly and easily assess how well a person's neutralizing antibodies fight infection from multiple variants of COVID-19 such as Delta and the newly discovered Omicron variant.
A common strategy to make vaccines more powerful is to deliver them along with an adjuvant -; a compound that stimulates the immune system to produce a stronger response.
Immunotherapies are exhibiting better clinical benefit in the treatment of numerous cancers, particularly when used along with chemotherapy.